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Abstract
Introduction: Acute kidney injury (AKI) is associated with a high mortality of up to 60%. The mode of renal
replacement therapy (intermittent versus continuous) has no impact on patient survival. Sustained low efficiency
dialysis using a single-pass batch dialysis system (SLED-BD) has recently been introduced for the treatment of
dialysis-dependent AKI. To date, however, only limited evidence is available in the comparison of SLED-BD versus
continuous veno-venous hemofiltration (CVVH) in intensive care unit (ICU) patients with AKI.
Methods: Prospective, randomized, interventional, clinical study at a surgical intensive care unit of a university
hospital. Between 1 April 2006 and 31 January 2009, 232 AKI patients who underwent renal replacement therapy
(RRT) were randomized in the study. Follow-up was assessed until 30 August 2009. Patients were either assigned to
12-h SLED-BD or to 24-h predilutional CVVH. Both therapies were performed at a blood flow of 100 to 120 ml/min.
Results: 115 patients were treated with SLED-BD (total number of treatments n = 817) and 117 patients with CVVH
(total number of treatments n = 877).The primary outcome measure, 90-day mortality, was similar between groups
(SLED: 49.6% vs. CVVH: 55.6%, P = 0.43). Hemodynamic stability did not differ between SLED-BD and CVVH, whereas
patients in the SLED-BD group had significantly fewer days of mechanical ventilation (17.7 ± 19.4 vs. 20.9 ± 19.8,
P = 0.047) and fewer days in the ICU (19.6 ± 20.1 vs. 23.7 ± 21.9, P = 0.04). Patients treated with SLED needed
fewer blood transfusions (1,375 ± 2,573 ml vs. 1,976 ± 3,316 ml, P = 0.02) and had a substantial reduction in
nursing time spent for renal replacement therapy (P < 0.001) resulting in lower costs.
Conclusions: SLED-BD was associated with reduced nursing time and lower costs compared to CVVH at similar
outcomes. In the light of limited health care resources, SLED-BD offers an attractive alternative for the treatment of
AKI in ICU patients.
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* Correspondence: vedat.schwenger@med.uni-heidelberg.de
† Contributed equally
1Department of Nephrology, University of Heidelberg, Im Neuenheimer Feld
672, Heidelberg 69120, Germany
Full list of author information is available at the end of the article
Schwenger et al. Critical Care 2012, 16:R140
http://ccforum.com/content/16/4/R140
© 2012 Schwenger et al.; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Introduction
About 5 to 10% of patients admitted to the ICU develop
acute kidney injury (AKI) requiring renal replacement
therapy (RRT) [1]. AKI is an independent risk factor for
mortality [1-3] and independently associated with the
development of end-stage renal disease [4,5]. AKI is there-
fore not only one of the most important complications,
but also one of the most cost-intensive interventions in
ICU patients.
Recent randomized clinical trials showed no survival
benefit or improved renal recovery in critically ill patients
with AKI depending on the RRT, that is continuous RRT
(CRRT) vs. intermittent renal replacement therapy (IRRT)
[6-8], or the delivered dose of RRT [9-11]. More recently,
newer hybrid techniques such as sustained low efficiency
dialysis using a single-pass batch dialysis system (SLED-
BD) which combines several advantages of both CRRT
and IRRT have been introduced into clinical practice
[12,13]. However, only small randomized controlled trials
are available that compare SLED-BD with CRRT methods.
Therefore, our study aimed to investigate survival, hemo-
dynamic stability, practicability and costs in critically ill
patients with AKI treated with either SLED-BD or contin-
uous veno-venous hemofiltration (CVVH).
Materials and methods
Study settings
The renal replacement therapy study in ICU patients
(RESCUE) is a prospective, randomized intention-to-treat
study, conducted to compare two different RRTs in criti-
cally ill patients with AKI. The study was performed
between 1 April 2006 and 31 January 2009 in the surgical
ICU of the University of Heidelberg, Germany. The fol-
low-up phase continued until 30 August 2009.
The study was registered [14] and the study protocol
was approved by the local ethics committee (approval
number 357/2005) and performed in accordance with the
declaration of Helsinki and German Federal Guidelines.
The integrity of data collection was independently veri-
fied by the Section of Medical Statistics, Technische
Hochschule Mittelhessen (University of Applied
Sciences), Germany. No manufacturer of dialysis devices
was involved in the study design, data analysis or manu-
script preparation.
Study population
All patients admitted to the surgical ICU were screened
for eligibility. Critically ill patients with AKI requiring RRT
were eligible for enrolment if they were 18 years of age or
older and met at least one of the following inclusion cri-
teria: oligoanuria (urine output < 500 ml in a 24-hour per-
iod) and exclusion of post renal AKI, volume overload and
unresponsiveness to fluid resuscitation measures, serum
potassium > 6.5 mmol/l and an acute rise in plasma urea
nitrogen level above 70 mg/dl.
Written informed consent was obtained from the
patient or legal health care representative. Exclusion cri-
teria were end-stage renal disease, preexisting chronic
kidney disease stage 4 to 5 according to the Kidney Dis-
ease Outcome Quality Initiative (KDOQI), participation
in another study, pregnancy and consent denial. Patients
who had previously received renal replacement therapy
during the same admission were ineligible for inclusion.
Randomization and treatment assignments
Patients were randomly assigned to two treatment groups
in a ratio of 1:1 using a computer-generated randomiza-
tion modus. Patients allocated to the SLED-BD treatment
(Genius®, Fresenius Medical Care, Bad Homburg,
Germany) were assigned to receive 12-h of dialysis with a
blood flow rate of 100 to 120 ml/min. For all SLED treat-
ments, high-flux polysulfone filters (FX 50, Fresenius Med-
ical Care, Bad Homburg, Germany) were used. In the
Genius® dialysis device the dialysate is stored in an air-free
90-liter glass container (batch system) [15-17] (Additional
file 1).
Patients randomly assigned to the CVVH-group (Prisma,
Gambro Hospal, Lyon, France) were treated with 35 ml/kg
per hour replacement fluid in predilution. Treatment was
scheduled for 24-h and blood flow was maintained
between 100 and 120 ml/min. For all CVVH treatments,
high-flux polysulfone filters (Asahi KASEI APS-650, Asahi
Kasei Medical Co, Ltd., Japan) were used.
It was in the responsibility of the ICU physician to
decide whether to prolong or shorten the duration of
treatment and whether to give blood transfusions; how-
ever, transfusion of packed red blood cells was recom-
mended if the hemoglobin concentration fell below
7.0 g/dl [18].
Study outcomes
The primary outcome measure of patients with AKI in the
ICU was 90-day mortality. Secondary outcome measures
included in-hospital mortality, mortality assessed until
30 August 2009, hemodynamic stability, time taken to
recovery of renal function, duration of mechanical ventila-
tion and length of ICU stay. A hypotensive episode was
defined as an acute drop of systolic blood pressure below
80 mmHg or > 20% from baseline. The time to recovery
of renal function was defined as the time from first RRT
to last RRT and continuation of medical therapy. Recovery
of renal function was defined as increasing diuresis
without further need for RRT, stable or decreasing serum
creatinine without RRT. Cessation of RRT was the respon-
sibility of the ICU physician. Additional endpoints were
treatment time of RRT (assessed at each day from 12 pm
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to 12 pm), number of packed red cell transfusions, nursing
time spent for RRT and costs. Nursing time directly spent
for RRT was documented at each RRT device contact. For
the economic evaluation of the renal replacement modal-
ity, we documented the costs of nursing spent for each
RRT, the costs of consumed RRT supplies and equipment,
and the reimbursement by the German DRG (German
diagnosis-related groups) system. All cost data were
reported in euros.
Statistical analysis
All analyses were performed according to the intention-
to-treat principle. Probabilities of survival were calcu-
lated by the Kaplan Meier estimate and compared by
application of the log-rank or Mantel-Haenszel test.
Comparison of qualitative data was performed using 2 ×
2 contingency tables and Chi square analysis, with or with-
out Yates’ correction or by Fisher’s exact test. For quanti-
tative analysis, differences between means were identified
using the Wilcoxon rank test for independent variables.
Statistical significance was accepted at P < 0.05. Data in
tables are presented as mean ± standard deviation.
All statistical analyses were performed using PCS soft-
ware (PC statistics 5.0, O. Hoffmann, Giessen, Germany).
Results
Study enrollment and demographics
Between 1 April 2006 and 30 January 2009, 1,776 patients
admitted to the surgical ICU were screened for eligibility;
of these, 465 received RRT, 233 declined consent or failed
the inclusion criteria and 232 were randomly assigned to
one of the two treatment cohorts, SLED-BD: n = 115 vs.
CVVH: n = 117 (Figure 1). A total of 15 randomized
patients had an accidental change of the treatment modal-
ity in the daily routine. In detail, eight patients were ran-
domized for CVVH but changed to SLED-BD, two were
randomized to SLED-BD and changed to CVVH; three
patients were randomized to SLED-BD and two to CVVH,
but died before receiving any RRT.
As shown in Table 1, baseline characteristics and
comorbidities were similar in both groups. Sepsis was the
leading cause of AKI. Patients were comparable with
respect to the mean Acute Physiology and Chronic Health
Evaluation II score (APACHE II), the mean Therapeutic
Intervention Scoring System (TISS) and the Simplified
Acute Physiology Score II (SAPS II).
Treatment parameters and study outcomes
Treatment and follow-up data are presented in Tables 2
and 3. The primary outcome measure, 90-day mortality,
as well as ICU mortality, in-hospital mortality, and long-
term mortality (as assessed by August 30, 2009) were
high in the study population but did not differ between
the SLED and the CVVH groups (Table 3). Figure 2 gives
the Kaplan-Meier survival estimates for both groups. Pre-
and post-treatment systolic and diastolic blood pressure
values and vasopressors were not significantly different;
however, post-treatment systolic blood pressure tended
to be higher in the SLED cohort (P = 0.05) (Table 3).
SLED was accomplished with a significantly higher effec-
tive blood flow (P < 0.001), whereas ultrafiltration (UF)
volume (P = 0.08), the fluid balance and the number of
hypotensive episodes did not differ between groups
(Tables 2 and 3). The decrease in body temperature during
treatment was more pronounced in the SLED group
(Table 2) and was negatively correlated with change in
diastolic but not systolic blood pressure (r = -0.175,
P = 0.008) (Table 2).
Duration of mechanical ventilation (P = 0.047) and of
ICU-stay (P = 0.038), and time to renal recovery (P =
0.049) were significantly shorter in the SLED group
(Table 3). The average number of treatments was similar
in both groups (P = 0.096). Although a 12-h treatment
period for SLED, and a 24-h treatment period for CVVH
was anticipated, the average of the delivered treatment
time differed only by 1 h (P = 0.024). If the incomplete
first and last treatments (due to the assessment from
12.00 pm to 12.00 pm, see methods) were excluded, the
average treatment time for CVVH was 19.9 ± 3.64 h
(median 20.8 h) (Table 2). The delivered CVVH dose was
below the prescribed dose at 31 ml/kg per h, but within
the recommended dose for CVVH treatment [19]. Solute
clearance (as demonstrated by urea and phosphate
values) was more effective in the SLED-treated patients
than in the CVVH-treated patients (Table 2).
The number of dialysis catheters used per treatment did
not differ between both groups. However, the number of
membranes used per patient was higher in the SLED
group (Table 4). The quantity of blood transfusions given
was significantly higher in the CVVH than in the SLED
patient cohort, although the mean daily heparin dose did
not differ (Table 2). No difference was observed in the
administration of fresh frozen plasma.
Economics
The nursing time spent for RRT was significantly higher
in the CVVH group than in the SLED group (Table 4).
Evaluating the expenditure and lower direct costs for
providing RRT, SLED used with a specific AKI mem-
brane was associated with lower costs of about €220 per
patient compared with CVVH (Tables 4 and 5). If con-
ventional high-flux membranes were used instead of spe-
cific AKI membranes (as was performed in our study),
the cost difference increased to €1,300 per patient (the
acquisition costs for the Genius® facility were considered
with an advance payment of €8 per treatment). SLED,
using a conventional high-flux membrane, was associated
with significantly lower costs even after consideration of
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the higher reimbursement for CVVH by the German
DRG system (Table 5).
Discussion
In this prospective randomized study, we compared
CVVH with a targeted dose of 35 ml/kg per h with
SLED-BD for the treatment of AKI in ICU. In line with
other reports on patients with sepsis and multi-organ
failure, we found high 90-day mortality, and no differ-
ences in mortality at any time (for ICU-, in-hospital, or
long-term mortality) [1,7,8].
Recent data demonstrate that neither the technique of
RRT [7,8] nor the dose of RRT [9-11] had an impact on
patient survival. In the light of the markedly higher costs
of CRRT, it was therefore suggested that, in the absence
of a survival benefit of CRRT, intermittent hemodialysis
(IHD) should be the preferred treatment modality for
AKI in critically ill patients [20]. In the meantime, the
newer hybrid technique, SLED, which combines the
hemodynamic stability of CRRT with a more favorably
priced dialysis technique, has been introduced as a new
cost-effective approach to the treatment of AKI in the
Figure 1 Enrolment, randomization and inclusion of study patients. Numbers of ICU patients enrolled in the study and randomly assigned
to different treatment groups.
Table 1 Baseline characteristics of study patients.
All (n = 232) SLED (n = 115) CVVH (n = 117) P
Sex (female) 75 (32.3%) 43 (37.4%) 32 (27.4%) 0.135*
Age (years) 66.2 ± 12.4 66.6 ± 12.6 65.8 ± 12.1 0.252**
Body weight (kg) 80.4 ± 17.5 80.7 ± 19.2 80.2 ± 15.6 0.407**
Body mass index (kg/m2) 27.2 ± 5.2 27.5 ± 5.6 26.9 ± 4.7 0.417**
Diabetes prevalence 54 (23.4%) 25 (21.7%) 29 (25.0%) 0.667*
Coronary artery disease 75 (33.2 %) 39 (35.5%) 36 (31.0%) 0.573*
Cancer 91 (39.6%) 45 (39.1%) 46 (40.0%) 0.999*
Liver transplantation 46 (19.9%) 21 (18.3%) 25 (21.6 %) 0.644*
Kidney transplantation 2 (0.9%) 0 2 (1.7%) 0.481*
Serum creatinine (mg/dl) 2.57 ± 1.17 2.59 ± 1.33 2.55 ± 1.00 0.319**
Urea (mg/dl) 135.1 ± 56.7 132.7 ± 59.7 137.3 ±53.9 0.203**
Urine output (ml/24h) 2713 ± 2022 2786 ± 1970 2643 ± 2 081 0.275**
Oliguria
(urine output < 500 ml/24h)
21 (14.0%) 9 (12.3%) 12 (15.6%) 0.368***
SAPS 68.5 ± 15.5 69.5 ± 14.0 67.6 ± 16.7 0.353**
Apache 31.8 ± 8.2 31.3 ± 8.7 32.2 ± 7.8 0.315**
TISS 48.7 ± 6.2 49.0 ± 5.4 48.5 ± 6.9 0.201**
Sepsis 121 (54.0%) 60 (54.0%) 61 (54.1%) 0.902*
All values are expressed as number (percent) or mean ± SD; statistical analyses were performed for SLED versus CVVH. *2 × 2 table Chi square test with Yates’
correction; **one-tailed Wilcoxon test. *** Fisher’s exact test. Apache: Acute Physiology and Chronic Health Evaluation II score; TISS: Therapeutic Intervention
Scoring System; SAPS II: Simplified Acute Physiology Score II; SLED: sustained low efficiency dialysis; CVVH: continuous veno-venous hemofiltration.
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ICU [13,21,22]. The hemodynamic stability of this
approach was demonstrated in the first prospective smal-
ler investigations [12,21]. This study is, to the best of our
knowledge, the first larger randomized study comparing
SLED-BD with CVVH. As demonstrated, blood pressure
was well maintained and even tended to be higher after
treatment in the SLED group compared to CVVH,
although the net UF and the use of vasopressors were
not significantly different with either therapy. The
decreased temperature of the non-heated dialysate during
SLED-BD might have accounted for this; and in fact, the
decrease in body temperature after treatment in the
SLED-BD patient cohort was greater than in the CVVH
treated cohort. However, the maintained hemodynamic
stability in the SLED treated group may also be the result
of the extended duration of the SLED treatment pre-
scribed by the ICU physician in charge. Primarily SLED
was prescribed to deliver a treatment time of 12 hours;
however, the actual delivered treatment time was pro-
longed by the ICU physician to 14.9 hours. In contrast,
the actual treatment time in the CVVH cohort was
reduced but was still significantly higher than the treat-
ment time for SLED. Although the average treatment
time seems rather low, we assume that the actual deliv-
ered treatment time for CVVH in this study reflects clini-
cal practice, at least in surgical units, where treatment is
Table 2 Parameters and laboratory results during renal replacement therapy (RRT).
All (n = 232) SLED (n = 115) CVVH (n = 117) P*
Norepinephrine (µ/kg/min) 0.128 ± 0.129 0.137 ± 0.149 0.121 ± 0.11 0.266
Epinephrine (µ/kg/min) (n = 30) 0.100 ± 0.359 0.156 ± 0.233 0.243 ± 0.456 0.273
Dobutamine (µ/kg/min) (n = 109) 2.561 ± 1.446 2.710 ± 1.288 2.425 ± 1.576 0.015
Furosemide dose (mg/24h) 298.4 ± 239.5 311.0 ± 259.2 286.1 ± 218.9 0.365
Urine output (ml/24h) 1945 ± 1647 1860 ± 1693 2027 ± 1605 0.121
Duration of treatment (h)
(values after exclusion of incomplete first and last treatment, see Methods)
16.7 ± 4.8 14.9 ± 4.4 15.9 ± 4.2
(19.9 ± 3.64)
0.024
Average number of treatments 7.67 ± 8.39 7.50 ± 8.89 7.83 ± 7.92 0.096
Absolute number of treatments 1694 817 877
Net ultrafiltration (ml/24h) 1730 ± 1099 1850 ± 1179 1617 ± 1008 0.089
Fluid balance (ml/24h) 636 ± 1405 533 ± 1364 736 ± 1443 0.195
Effective blood flow (ml/min) 113.2 ± 15.5 125.7 ± 9.65 101.7 ± 9.82 < 0.001
Effluent flow (ml/h) 2390 ± 426
Effluent flow rate (ml/kg/h) 30.87 ± 7.66
Dialysate flow (ml/h) 120.9 ± 20.3
Body temperature before RRT (°C) 36.5 ± 0.7 36.6 ± 0.7 36.4 ± 0.6 0.002
Change in body temperature during RRT (°C) -0.2 ± 0.7 -0.3 ± 0.7 - 0.17 ± 0.7 0.011
Heparin (IU/24h) 4874 ± 4004 4554 ± 3594 5191 ± 4438 0.200
Hemoglobin (g/dl) 9.01 ± 0.95 9.06 ± 0.92 8.97 ± 0.97 0.276
Hematocrit (%) 0.29 ± 0.32 0.27 ± 0.03 0.30 ± 0.45 0.237
White blood cell count (/nl) 13.4 ± 7.3 13.0 ± 6.3 13.7 ± 8.2 0.460
Thrombocytes (/nl) 157.8 ± 123.5 157.2 ± 133.5 158.5 ± 113.4 0.177
C-reactive protein (mg/l) 107.5 ± 63.1 110.2 ± 66.8 105.1 ± 59.4 0.392
Albumin (g/l) 23.9 ± 4.6 24.1 ± 4.6 23.7 ± 4.6 0.306
pH 7.38 ± 0.05 7.38 ± 0.06 7.38 ± 0.05 0.242
HCO3- (mmol/l) 23.6 ± 2.55 23.6 ± 2.47 23.6 ± 2.62 0.478
Lactate (mg/dl) 21.1 ± 25.3 19.4 ± 22.9 22.7 ± 27.5 0.260
Serum creatinine pre-treatment (mg/dl) 1.85 ± 0.80 1.77 ± 0.90 1.92 ± 0.68 0.007
Serum creatinine after treatment (mg/dl) 1.46 ± 0.75 1.26 ± 0.80 1.66 ± 0.65 < 0.001
Urea pre-treatment (mg/dl) 113.5 ± 48.3 105.7 ± 55.7 121.2 ± 38.4 0.002
Urea after treatment (mg/dl) 87.1 ± 35.6 68.4 ± 31.2 105.5 ± 29.7 < 0.001
Phosphate pre-treatment (mmol/l) 1.39 ± 1.50 1.42 ± 2.03 1.35 ± 0.52 0.018
Phosphate after treatment (mmol/l) 1.02 ± 0.37 0.88 ± 0.34 1.18 ± 0.35 < 0.001
Calcium (mmol/l) 2.07 ± 0.19 2.04 ± 0.16 2.10 ± 0.22 0.007
Total packed red blood cell Transfusion per patient (ml) 1680 ± 2981 1375 ± 2573 1976 ± 3316 0.019
Total fresh frozen plasma per patient (ml) 1586 ± 4290 1285 ± 3942 1878 ± 4603 0.115
All values are expressed as daily mean (unless otherwise indicated) ± SD; statistical analyses were performed for SLED versus CVVH; *one-tailed Wilcoxon test.
SLED: sustained low efficiency dialysis; CVVH: continuous veno-venous hemofiltration.
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often interrupted due to bleeding complications, opera-
tive revisions or consecutive investigations. In addition,
one has to consider, that we evaluated the treatment time
from 12 pm to 12 pm, which means that if a treatment
starts in the afternoon of the first day at 6 pm, the first
session was documented as a 6 h treatment (from start
until midnight). This applies also for the last treatment.
When we excluded the incomplete first and last CVVH
treatments, the mean duration of treatment was 19.9 ±
3.64 hours. Although, this is in line with current practice
[10], this emphasizes that the method of time evaluation
of treatment is of great importance and should be given.
It is of interest that in almost all studies on CRRT, the
prescribed and delivered doses are mentioned, but the
treatment time per day and the time of interruption of
treatment are not [7-9,23]. This is of importance, as
some studies demonstrate that the time of interruption
of CRRT might be relevant [11].
Our data illustrate that SLED treatment was adapted
by the intensivists to a CRRT modality. In the face of
Table 3 Primary and secondary outcomes.
All (n = 232) SLED (n = 115) CVVH (n = 117) P
Death from any cause by day 90 122 (52.6 %) 57 (49.6 %) 65 (55.6 %) 0.434**
Death from any cause up to 30 August 2009 155 (66.8 %) 76 (66.1 %) 79 (67.5 %) 0.926**
In-hospital mortality 119 (51.3 %) 57 (49.6 %) 62 (53.0 %) 0.696**
Mortality in ICU 98 (42.2 %) 49 (42.6 %) 49 (41.9 %) 0.984**
Mechanical ventilation 205 (88.4%) 101 (87.8%) 104 (88.9%) 0.962**
Days of mechanical ventilation 1 9.4 ± 19.7 17.7 ± 19.4 20.9 ± 19.8 0.047*
Days in intensive care unit 21.7 ± 21.1 19.6 ± 20.1 23.7 ± 21.9 0.038*
Recovery of kidney function in days after RRT initiation 10.2 ± 14.5 10.0 ± 15.2 10.5 ± 14.0 0.049*
BP syst pre-treatment (mmHg) 124.8 ± 14.0 125.1 ± 14.6 124.6 ± 13.5 0.434*
BP syst after treatment (mmHg) 126.3 ± 16.4 128.3 ± 17.1 124.3 ± 15.6 0.051*
BP diast pre-treatment (mmHg) 60.7 ± 10.3 60.7 ± 10.7 60.7 ± 10.0 0.420*
BP diast after treatment (mmHg) 61.1 ± 10.7 61.8 ± 11.3 60.3 ± 10.2 0.250*
Hypotensive episodes 1.6 ± 1.5 1.5 ± 1.4 1.8 ± 1.6 0.077*
All values are expressed as number (percent) or mean ± SD; statistical analyses were performed for SLED versus CVVH. *One-tailed Wilcoxon test; **2 × 2 table
Chi-Square test with Yates’ correction. BP syst: systolic blood pressure; BP diast: diastolic blood pressure; SLED: sustained low efficiency dialysis; CVVH: continuous
veno-venous hemofiltration.
Figure 2 Probabilities of survival in sustained low efficiency dialysis (SLED) and continuous veno-venous hemofiltration (CVVH)
treatment groups (Kaplan-Meier estimates) during the first 90 days. Mortality at 90 days was similar in ICU patients with acute kidney
disease (AKI) treated with SLED-BD or with CVVH.
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newer hybrid techniques the classical differentiation in
CRRT (mostly performed by CVVH with convective
elimination of solutes) and IRRT (hemodialysis with dif-
fusive elimination of solutes) may become obsolete. One
has to keep in mind that adapting the treatment time of
a dialysis device to a CRRT modality, resulted not only
in a higher solute clearance but might lead to a poten-
tially dangerous underdosing of, for example, anti-infec-
tive agents [24].
Another aspect, apart from the actual delivered treat-
ment time, is that it still remains a matter of debate
when to start, but also when to stop RRT, and this dis-
cussion is ongoing. It might be considered that the start
of RRT in our study was too early (or too late), however,
even today, criteria for starting and ending RRT remain
arbitrary in many respects.
A potentially complicating factor is the more intensi-
fied anticoagulation for CRRT due to the longer treat-
ment time required to prevent clotting of the
extracorporeal circuit. In fact, earlier reports have
demonstrated a significantly lower need for anticoagula-
tion in SLED-treated patients [12,21,25]. However, the
total amount of heparin administered in our study was
slightly, but not statistically significantly lower in
patients treated with SLED. This clearly overcomes the
prejudice that CRRT per se requires a more intensified
anticoagulation; the need for anticoagulation seems
rather a consequence of the treatment time than a con-
sequence of the treatment modality used. We do not
believe that a slightly but insignificantly increased
amount of heparin infused in CVVH patients in this
study resulted in a higher quantity of transfused red
packed cells. We may eventually only speculate as to
whether small but insignificant differences in volume
balance might be causative for the observed differences
in blood transfusions or in the number of days of
mechanical ventilation. On the other hand, the longer
duration of mechanical ventilation might be responsible
for the slight difference observed in the time for recov-
ery of kidney function [26].
Costs for medical devices and treatment are of increas-
ing importance. CVVH treatment in general consumes
greater health care resources than dialysis techniques
[20]. We evaluated the modality-associated costs of
SLED, taking the acquisition costs for the dialysis facility
into account, and compared them with CVVH for ICU
patients with AKI, based on the average purchase price,
number of membranes used, personnel costs and the
reimbursement by the German DRG system. SLED was
associated with a reduction in cost for providing RRT. In
addition, a further cost reduction for the SLED modality
was achieved in our department by substituting the speci-
fic AKI membrane by a conventional high-flux mem-
brane. The costs for RRT (treatment and nursing costs)
differed by about €220 per ICU patient. In fact, the differ-
ence would be much higher using conventional high-flux
membranes rather than the specific AKI membranes
used in our study. The difference was about €1,300 per
patient. Further cost savings may be achieved by the use
of a newer biocompatible low-flux membrane, which has
almost equivalent efficacy to high-flux membranes at
lower costs [27,28], or by the substitution of heparin
anticoagulation by using regional citrate anticoagulation
protocols [29]. Though a large number of membranes
were used this is in line with other studies [9]. During
cost calculations, one has also to consider that the hospi-
tal reimbursement by the German DRG system is mark-
edly higher for CVVH compared to dialysis devices.
Taking the lower direct costs of SLED and the higher
reimbursement for CVVH into account, our data demon-
strate that CVVH remains still more expensive than
SLED without superior patient outcome, at least in this
Table 4 Dialysis equipment and nursing time per patient.
SLED (n =
115)
CVVH (n =
117)
P*
Number of membranes used 14.3 ± 15.3 7.56 ± 8.54 <
0.001
Number of dialysis catheters
used
1.74 ± 1.44 1.70 ± 1.89 0.294
Nursing time spent (minutes)
< 1 9.36 ± 14.7 14.3 ± 41.9 0.131
1 to 5 3.64 ± 4.63 6.75 ± 13.2 0.136
> 5 7.24 ± 9.51 12.1 ± 17.0 <
0.001
*One-tailed Wilcoxon test. SLED: sustained low efficiency dialysis; CVVH:
continuous veno-venous hemofiltration.
Table 5 Estimated costs of renal replacement therapy (RRT).
SLED (using a high-
flux membrane)
SLED (using an AKI
membrane)
CVVH
RRT costs/day (acquisition cost for the Genius and water preparation device included with
€8/treatment. Number of membranes used per treatment were considered)
€63.2 €206.7 €209.3
Overall modality costs per treatment (nursing included, without technician, physician and
other medical staff)
€96.8 €240.4 €258.9
Reimbursement for modality/day
(German DRG system)
€221.0 €221.0 €300.0
DRG: German diagnosis-related groups; SLED: sustained low efficiency dialysis; CVVH: continuous veno-venous hemofiltration.
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small patient cohort of surgical ICU patients. Therefore,
using a SLED-BD system in AKI patients in ICU has dis-
tinct advantages with regard not only to cost effective-
ness, but also patency and practicability.
Limitations
There are several limitations of the study. First, the
results of this study are from a small patient cohort
from a surgical ICU and therefore may not be easily
extrapolated to non-surgical ICU patients. Second, the
power of the study may be insufficient to finally judge
whether one or the other treatment modality is superior
in terms of survival. However, the power is clearly suffi-
cient to discriminate differences in economics; with a
significance level of 0.05, the estimated power is 99% for
the number of membranes used and 81% for more than
5 minutes nursing time spent directly on the device
(data not shown in the results). Third, the timing of the
start and end of RRT is still a matter of debate but
might have influenced the results in this study. Finally,
though the targeted treatment times for CVVH and
SLED-BD differed by 12 hours, the difference of the
delivered treatment time was much lower.
Conclusions
Newer hybrid SLED techniques using a single-pass
batch system demonstrated similar patient outcomes
and hemodynamic properties compared to CVVH but
were associated with a more favorable price. In the light
of limited health care resources, SLED offers an attrac-
tive alternative for treatment of AKI in ICU patients.
Key messages
• Mortality and hemodynamic stability did not differ
in AKI patients treated either with SLED or CVVH
• SLED treatment was associated with a lower quan-
tity of blood transfusions given, a shorter ICU stay,
shorter duration of mechanical ventilation and faster
recovery of renal function
• SLED was accompanied with reduced nursing time
spent for RRT and lower costs for providing RRT
Additional material
Additional file 1: figure showing a single-pass batch dialysis device
(with courtesy Fresenius Medical Care, Germany). Fresh dialysate is
aspirated from the top of the tank via a roller pump, whereas spent
dialysate is returned to the bottom of the glass tank. Recently, the nearly
complete separation of spent and fresh dialysate was demonstrated in
detailed studies [15,30]. (1) Double-sided blood as well as dialysis pump.
(2) Air detector between pump and membrane. (3) Dialysis membrane.
(4, 5) Air-free flow chamber. (6) Ultrafiltration pump (ultrafiltration is
removed by volumetric control via a roller pump). (7) Ultrafiltration
collecting-container. (8) Upper part of the tank (fresh dialysate is
removed from here). (9) Water boundary layer from fresh dialysate in the
upper part and spent dialysate in the lower part. (10) Spent dialysate.
(11) UV-radiator. (12) Glass container with thermal insulation.
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